Skip to main content

Table 1 Demographic, clinical, and pathologic characteristics from 12 patients at our institution

From: Clinical and immunologic characteristics of Japanese patients with anti-glomerular basement membrane disease: case reports and literature review

  All (n = 12)
Age, years (median [range]) 70 [32, 77]
Female, n (%) 2 (18)
BMI, kg/m2 (median [25%, 75%]) 21.5 [18.7, 23.9]
Diabetes mellitus, n (%) 5 (45)
Hypertension, n (%) 7 (64)
Anuria, n (%) 4 (36)
Hematuria, n (%) 12 (100)
Pulmonary interstitial opacities, n (%) 3 (25)
Pulmonary hemorrhage, n (%) 2 (17)
Hemoglobin, g/dL (median [25%, 75%]) 10.3 [8.3, 12.5]
Serum albumin, mg/dL (median [25%, 75%]) 2.7 [2.1, 3.1]
C-reactive protein, mg/dL (median [25%, 75%]) 16.7 [6.9, 28.4]
Serum creatinine, mg/dL (median [25, 75%]) 8.5 [5.2, 11.4]
eGFR, ml/min/1.73 m2 (median [25%, 75%]) 5 [3, 8]
Baseline urine protein, g/gCr (median [25%, 75%]) 1.4 [0.9, 2.4]
Anti-GBM antibody, IU/mL (median [range]) 214 [43, 16,385]
MPO-ANCA positive, n (%) 2 (18)
PR3-ANCA positive, n (%) 1 (9)
MPO-ANCA, IU/mL (median [range]) 40 [13.3, 67]
PR3-ANCA, IU/mL (median [range]) 1.5 [1.5, 1.5]
Global sclerosis (%) 6 (55)
Crescent (%) 12 (100)
Glomerular necrosis, n (%) 10 (91)
Interstitial inflammation, n (%) 12 (100)
Normal glomeruli, n (%) 0
Plasmapheresis, n (%) 8 (73)
Number of plasmapheresis, times (median [25%, 75%]) 18 [6, 20]
Oral steroids, n (%) 12 (100)
Oral steroid initial dose, mg/day (median [25%, 75%]) 40 [40, 60]
Steroid pulse therapy, n (%) 10 (91)
Number of steroid pulse therapies (n = 1/2/3) 6/0/4
  1. BMI body mass index, SLE systemic lupus erythematosus, eGFR estimated glomerular filtration rate, GBM glomerular basement membrane, IU international units, MPO-ANCA myeloperoxidase antineutrophil cytoplasmic antibody, PR3-ANCA proteinase 3 anti-neutrophil cytoplasmic antibody